Hematologic Cancers

Lenalidomide Maintenance Therapy After ASCT Shows Survival Benefit in Patients with Multiple Myeloma

Walter Alexander

September 2016, Vol 7, No 8 - Hematologic Cancers

A meta-analysis of overall survival (OS) in 3 clinical trials of lenalidomide (Revlimid) maintenance therapy after high-dose melphalan (Alkeran) and autologous stem-cell transplantation (ASCT) for multiple myeloma showed long-term disease control and prolonged OS. A slightly increased risk for a secondary primary malignancy is outweighed by the OS benefit, said lead investigator Philip McCarthy, MD, Roswell Park Cancer Institute, Buffalo, NY, in an oral presentation at the 2016 American Society of Clinical Oncology annual meeting. [ Read More ]

Venetoclax Shows Promising Efficacy in Relapsed or Refractory Acute Myelogenous Leukemia

Wayne Kuznar

September 2016, Vol 7, No 8 - Hematologic Cancers

Venetoclax (Venclexta) monotherapy has significant clinical activity in patients with acute myelogenous leukemia (AML) whose disease has relapsed or is resistant to chemotherapy and in those deemed unable to tolerate chemotherapy, according to a new study. The overall response rate (ORR) for venetoclax in the phase 2 single-arm study was 19%, with complete remissions in some patients. This was the first study to examine venetoclax monotherapy in patients with relapsed or refractory AML or untreated AML who are unfit for intensive therapy. [ Read More ]